Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”

Bibliographic Details
Published in:	Blood Cancer Journal
Main Authors:	K. H. Begna, X. Xu, N. Gangat, H. Alkhateeb, M. M. Patnaik, A. Al-Kali, M. A. Elliott, W. J. Hogan, M. R. Litzow, C. C. Hook, A. P. Wolanskyj-Spinner, A. Mangaonkar, R. He, A. Pardanani, M. Shah, R. P. Ketterling, A. Tefferi
Format:	Article
Language:	English
Published:	Nature Publishing Group 2022-04-01
Online Access:	https://doi.org/10.1038/s41408-022-00654-0

Similar Items

Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival
by: Ayalew Tefferi, et al.
Published: (2022-09-01)

One thousand patients with essential thrombocythemia: the Mayo Clinic experience
by: Naseema Gangat, et al.
Published: (2024-01-01)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
by: Ayalew Tefferi, et al.
Published: (2022-06-01)

P544: MOLECULAR PREDICTORS OF RESPONSE AND SURVIVAL IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA FOLLOWING VENETOCLAX AND HYPOMETHYLATING AGENTS
by: I. Johnson, et al.
Published: (2022-06-01)

Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
by: Ayalew Tefferi, et al.
Published: (2024-03-01)

Prognostic impact of <i>SF3B1</i> mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases
by: Faiqa Farrukh, et al.
Published: (2024-03-01)

FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(<i>DEK::NUP214</i>): The Mayo Clinic experience
by: Clifford M. Csizmar, et al.
Published: (2024-06-01)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
by: Maymona G. Abdelmagid, et al.
Published: (2023-02-01)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
by: Naseema Gangat, et al.
Published: (2023-03-01)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
by: Naseema Gangat, et al.
Published: (2022-06-01)

Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy
by: Isla M. Johnson, et al.
Published: (2025-02-01)

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm
by: Naseema Gangat, et al.
Published: (2022-12-01)

P1323: PREDICTION OF NON-RELAPSE MORTALITY BY EASIX AND HCT-CI SCORES IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT
by: A. Baranwal, et al.
Published: (2022-06-01)

Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
by: Mostafa Abdallah, et al.
Published: (2023-03-01)

Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation
by: Mrinal M. Patnaik, et al.
Published: (2019-06-01)

<i>SF3B1</i>-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity
by: Abhishek A. Mangaonkar, et al.
Published: (2022-02-01)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
by: Rimal Ilyas, et al.
Published: (2023-02-01)

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms
by: Terra L. Lasho, et al.
Published: (2018-02-01)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
by: Abhishek A. Mangaonkar, et al.
Published: (2022-02-01)

Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
by: Nickolas Steinauer, et al.
Published: (2024-03-01)

Targeted deep sequencing in primary myelofibrosis
by: Ayalew Tefferi, et al.
Published: (2016-12-01)

Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia
by: Naseema Gangat, et al.
Published: (2023-08-01)

Erythrocytosis associated with <i>EPAS1</i>(<i>HIF2A</i>), <i>EGLN1</i>(<i>PHD2</i>), <i>VHL, EPOR</i> or <i>BPGM</i> mutations: The Mayo Clinic experience
by: Naseema Gangat, et al.
Published: (2022-02-01)

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
by: Ayalew Tefferi, et al.
Published: (2023-03-01)

Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases
by: Saubia Fathima, et al.
Published: (2025-03-01)

P775: CLINICAL OUTCOMES AND SOCIOECONOMIC FACTORS IN CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE UNITED STATES USING THE NATIONAL CANCER DATABASE: 2004-2017
by: N. Mclaughlin, et al.
Published: (2022-06-01)

U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity
by: Talha Badar, et al.
Published: (2023-09-01)

P580: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
by: Rami Basmaci, et al.
Published: (2023-08-01)

Predictors of response to pacritinib therapy and survival among 60 Mayo Clinic patients with myelofibrosis treated outside of clinical trials
by: Maymona Abdelmagid, et al.
Published: (2025-03-01)

Genetic landscape and clinical outcomes of patients with <i>BCOR</i> mutated myeloid neoplasms
by: Anmol Baranwal, et al.
Published: (2024-02-01)

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
by: Aref Al-Kali, et al.
Published: (2023-04-01)

Clinical and molecular correlates of somatic and germline <i>DDX41</i> variants in patients and families with myeloid neoplasms
by: Talha Badar, et al.
Published: (2023-05-01)

Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
by: Maymona G. Abdelmagid, et al.
Published: (2023-08-01)

Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience
by: Ahmad Nanaa, et al.
Published: (2021-06-01)

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
by: Ayalew Tefferi, et al.
Published: (2023-07-01)

P734: CLONAL HEIRARCHY AND HETEROGENEITY IN STAG2M MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
by: Bahga Katamesh, et al.
Published: (2023-08-01)

Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels
by: Ayalew Tefferi, et al.
Published: (2018-08-01)

P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
by: Muhamad Oum, et al.
Published: (2023-08-01)

P722: CHARACTERISATION OF PHF6 MUTATIONS IN MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
by: Amrutha Sai Mittapalli, et al.
Published: (2023-08-01)

A retrospective analysis of upfront treatment strategies in chronic myelomonocytic leukemia: impact on survival and response patterns
by: Muhammad Yousuf, et al.
Published: (2025-10-01)